Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 11, 2014, Pages 1720-1725

  Lin, Yen Ting ^a   Wang, Yu Fen ^a   Yang, James Chih Hsin ^a   Yu, Chong Jen ^a   Wu, Shang Gin ^a   Shih, Jin Yuan ^a   Yang, Pan Chyr ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Crizotinib; Non small cell lung cancer; Renal cyst

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; CREATININE; CRIZOTINIB; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE METASTASIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; KIDNEY CYST; KIDNEY FUNCTION; LUNG ADENOCARCINOMA; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PSOAS MUSCLE; TREATMENT RESPONSE; TUMOR VOLUME; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; DRUG EFFECTS; ENZYMOLOGY; KIDNEY; KIDNEY POLYCYSTIC DISEASE; LUNG NEOPLASMS; METABOLISM; PATHOLOGY;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KIDNEY; KIDNEY DISEASES, CYSTIC; LUNG NEOPLASMS; MALE; MIDDLE AGED; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84925721057     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000326     Document Type: Article

References (15)

1. Ou SH. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug Des Devel Ther 2011;5:471-485.
2. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863-870.
3. FDA. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/202570s006lbl.pdf. [Last accessed on 2014 Mar 23]. 2013.
4. Bosniak MA. The current radiological approach to renal cysts. Radiology 1986;158:1-10.
5. Curry NS, Cochran ST, Bissada NK. Cystic renal masses: accurate Bosniak classification requires adequate renal CT. AJR Am J Roentgenol 2000;175:339-342.
6. Whelan TF. Guidelines on the management of renal cyst disease. Can Urol Assoc J 2010;4:98-99.
7. Crinò L, Kim D, Riely GJ, et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 2011;29:(Suppl; abstr 7514).
8. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-2394.
9. Carrim ZI, Murchison JT. The prevalence of simple renal and hepatic cysts detected by spiral computed tomography. Clin Radiol 2003;58:626-629.
10. FDA. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/202570s000lbl.pdf. [Last accessed on 2013 Oct 20]. 2011.
11. Pisters LL, el-Naggar AK, Luo W, Malpica A, Lin SH. C-met proto-oncogene expression in benign and malignant human renal tissues. J Urol 1997;158(3 Pt 1):724-728.
12. Zhou D, Tan RJ, Lin L, Zhou L, Liu Y. Activation of hepatocyte growth factor receptor, c-met, in renal tubules is required for renoprotection after acute kidney injury. Kidney Int 2013;84:509-520.
13. Horie S, Higashihara E, Nutahara K, et al. Mediation of renal cyst formation by hepatocyte growth factor. Lancet 1994;344:789-791.
14. Qin S, Taglienti M, Cai L, Zhou J, Kreidberg JA. c-Met and NF-kappaB-dependent overexpression of Wnt7a and -7b and Pax2 promotes cystogenesis in polycystic kidney disease. J Am Soc Nephrol 2012;23:1309-1318.
15. Qin S, Taglienti M, Nauli SM, et al. Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease. J Clin Invest 2010;120:3617-3628.